A Study of CDX-622 in Participants With Mild to Moderate Asthma
Part of paid clinical trials in San Francisco, California.
- Sponsor
- Celldex Therapeutics
- Study ID
- NCT07330778
- Phase
- PHASE1
- Status
- Recruiting
Conditions
- Mild to Moderate Asthma
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- CDX-622 — DRUGAdministered Intravenously
Study Details
This is a study to determine the safety, pharmacodynamics (PD), and pharmacokinetics (PK) of CDX-622 in adults with mild to moderate asthma.
Key Dates
- Start date
- Jun 30, 2026
- Status verified
- Jun 2026
- Primary completion
- Mar 31, 2027
- Completion
- Mar 31, 2027
Study Design
- Enrollment
- 12 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: CDX-622Eligible participants will receive a single dose
Primary Outcome Measure
To evaluate the safety and tolerability profile of CDX-622 in adults with mild to moderate asthma. [ Time Frame: Day 1 up to Day 85 (12 weeks) ]
Central Contacts
- Celldex Therapeutics844-723-9363
Locations (4)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of California, San Francisco | San Francisco | California | 94143 | Mariana Mosqueda Christine Nguyen |
| The University of Kansas Medical Center | Kansas City | Kansas | 66160 | |
| Brigham and Women's Hospital | Boston | Massachusetts | 02115 | Maria Angeles Cinelli |
| University of Pittsburgh Asthma and Environmental Lung Health Institute at UPMC | Pittsburgh | Pennsylvania | 15213 |